Silence Therapeutics plc (SLN)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-07) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-05) · 99.1 · 99.2 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-06) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-07) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-08) · 99.1 | ||
| 10-K/A | FY-2024 | |||
| 10-K | FY-2024 | 8-K (2025-02-27) · 99.1 · 99.2 | ||
| 20-FLatest | FY-2023 | — |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Income Statements | — |
|
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Comprehensive Income | — |
|
| Condensed Consolidated Statements of Operations (unaudited) | — |
|
| Consolidated Statements of Income (loss) | — |
|
| Consolidated Statements of Changes In Equity | — |
|
| Consolidated Statements of Comprehensive Income (loss) | ||
| Consolidated Cash Flow Statements | — |
|
| Consolidated Statements of Changes In Shareholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Benefit From R&d Credit | — |
|
| Capital Commitments and Contingent Liabilities | ||
| Capital Reserves | — |
|
| Cash and Cash Equivalents | — |
|
| Cash and Cash Equivalents and Short-term Investments | — |
|
| Commitments Under Short Leases | — |
|
| Contract Liabilities | ||
| Cybersecurity Risk Management, Strategy and Governance | — |
|
| Deferred Tax | — |
|
| Directors and Staff Costs | — |
|
| Equity-settled Share-based Compensation | ||
| Equity-settled Share-based Payments | — |
|
| Finance and Other Expenses | — |
|
| Finance and Other Income | — |
|
| Financial Assets At Amortized Cost | — |
|
| Financial Instruments and Risk Management | — |
|
| General Information | ||
| Goodwill | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Lease Liability | — |
|
| Leases | — |
|
| Loss Per Ordinary Equity Share (basic and Diluted) | — |
|
| Loss Per Share (basic and Diluted) | ||
| Notes To The Cash Flow Statement | — |
|
| Operating Loss | — |
|
| Other Assets | — |
|
| Other Income, Net | — |
|
| Other Income/(expense), Net | — |
|
| Other Intangible Assets | — |
|
| Pay Vs Performance Disclosure | ||
| Post Balance Sheet Events | — |
|
| Principal Accounting Policies | — |
|
| Property, Plant and Equipment | — |
|
| Related Party Transactions | ||
| Restructuring Charges | ||
| Revenue | ||
| Segment Reporting | ||
| Share Capital | — |
|
| Shareholders' Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| Taxation | — |
|
| Trade and Other Payables | — |
|
| Trade Receivables | — |
|